Despite Trade War, U.S. Drug Companies Turn to China for Key Cancer Treatments
U.S. drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be worth up to $25 billion.
U.S. drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be worth up to $25 billion.